Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer

被引:6
|
作者
Mannuel, Heather D.
Hussain, Arif
机构
[1] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA
[3] Baltimore Vet Affairs Med Ctr, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Biochem, Baltimore, MD 21201 USA
关键词
external-beam radiation therapy; Gleason score; prostate-specific antigen; radical prostatectomy;
D O I
10.3816/CGC.2006.n.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Locally advanced prostate cancer encompasses several disease states that vary in the risk for progression and recurrence after initial treatment. Further, the optimal treatment strategies for locally advanced prostate cancer are continuing to evolve, reflecting the complex nature of this disease state. For many patients, clinical experience demonstrates that a combined approach of locally directed therapy and systemic therapy is likely to provide better long-term outcome than single-modality therapy. Randomized studies have established hormone ablation with external-beam radiation as an important form of treatment for this group of patients. However, additional progress needs to be made, particularly in the subgroup of patients with very high-risk disease features. As the optimal integration of local and systemic treatments becomes more clearly defined, the long-term prognosis for patients with high-risk locally advanced prostate cancer will improve.
引用
收藏
页码:43 / 49
页数:7
相关论文
共 50 条
  • [1] Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer
    See W.A.
    Current Treatment Options in Oncology, 2003, 4 (5) : 351 - 362
  • [2] Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer
    Iwamoto, Hiroaki
    Izumi, Kouji
    Makino, Tomoyuki
    Mizokami, Atsushi
    CANCERS, 2022, 14 (07)
  • [3] Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer
    Thoms, John
    Goda, Jayant S.
    Zlotta, Alexendre R.
    Fleshner, Neil E.
    van der Kwast, Theodorus H.
    Supiot, St Phane
    Warde, Padraig
    Bristow, Robert G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2011, 8 (02) : 107 - 113
  • [4] Multimodal treatment of high-risk and locally advanced prostate cancer
    Preisser, Felix
    Tilki, Derya
    UROLOGIE, 2022, 61 (12): : 1341 - 1344
  • [5] Treatment strategies for high-risk locally advanced prostate cancer
    Rosenthal, Seth A.
    Sandler, Howard M.
    NATURE REVIEWS UROLOGY, 2010, 7 (01) : 31 - 38
  • [6] The role of surgery for high-risk prostate cancer
    Ucer, Oktay
    Muezzinoglu, Talha
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (01): : 21 - 24
  • [7] Man With Locally Advanced, High-Risk Prostate Cancer Asks About Adding Chemotherapy to His Treatment
    Bourlon, Maria T.
    Mora, Mauricio
    Hinojosa-Fano, Juan
    Martinez-Benitez, Braulio
    Amini, Arya
    Castillejos-Molina, Ricardo
    Glode, L. Michael
    ONCOLOGY-NEW YORK, 2016, 30 (01): : 94 - +
  • [8] High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key
    Terlizzi, Mario
    Bossi, Alberto
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 38 : 14 - 16
  • [9] The importance of local control in high-risk locally advanced prostate cancer
    Sridharan, S.
    Warde, P.
    CURRENT ONCOLOGY, 2012, 19 : S6 - S12
  • [10] ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
    McLaughlin, Patrick W.
    Liss, Adam L.
    Nguyen, Paul L.
    Assimas, Dean G.
    D'Amico, Anthony V.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    Keol, Sameer R.
    Liauw, Stanley L.
    Lloyd, Shane
    Movsas, Benjamin
    Prestidg, Bradley R.
    Showalter, Timothy N.
    Taira, Al V.
    Vapiwal, Neha
    Davi, Brian J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 1 - 10